The Antidote Formula in Snake Blood: Rattlesnake Protein Mixture Blocks Lethal Venom

Many snakebites worldwide occur in rural areas with scarce medical resources, yet lifesaving antivenoms are often expensive, difficult to store and distribute, and inconsistent in the protection they provide against different snake species. Researchers are now turning their attention to venomous snakes themselves: because rattlesnakes can withstand venom that accidentally enters their bodies, the defensive molecules in their blood may offer a blueprint for a new generation of antidotes.

A team led by Sean B. Carroll at the University of Maryland studied FETUA proteins in western diamondback rattlesnake serum. These natural proteins can inhibit snake venom metalloproteinases, which damage blood vessels and tissues and are major components responsible for bleeding, local necrosis, and systemic injury caused by viper venom. The study was published on July 29 in the *Proceedings of the National Academy of Sciences*, and *Nature* subsequently highlighted its findings.

Experiments showed that individual FETUA proteins had different strengths: some were better at reducing bleeding, while others inhibited enzyme activity, but none could completely prevent the death of experimental animals when used alone. After the researchers adjusted the formulation based on complementary effects, the protein mixture completely neutralized an otherwise lethal dose of rattlesnake venom in mice while limiting bleeding and tissue degradation.

By weight, the optimized mixture was approximately ten times as potent under experimental conditions as a commercial sheep-derived rattlesnake antivenom, and it showed protective effects against venom from several viper species. This suggests that conserved inhibitory proteins in snake blood may overcome some species differences and help address the challenge that conventional antibody preparations face from the highly variable composition of venoms. However, this figure comes from laboratory and animal models and cannot be directly interpreted as indicating the dose required in humans or a tenfold improvement in clinical efficacy.

The strategy does not center on directly collecting large quantities of snake blood, but on identifying effective protein combinations that could later be produced through recombinant methods. If a stable, scalable formulation can be established, it could theoretically reduce the batch variability and supply constraints associated with producing antibodies by immunizing large animals. The research team believes veterinary applications may become available sooner than human medicines, but no clinical trial results or approval timeline have yet been presented.

The biggest immediate gap is that snake venom does not consist solely of metalloproteinases. A single venom can contain numerous toxins from multiple families, while this study targeted only one major family. Safety, immune responses, timing of administration, coverage across different snake species, and the cost of large-scale production also remain to be clarified. The team is extending the same approach to other major toxin families in viper venom. Whether multiple sets of inhibitory proteins can be integrated into a truly broad-spectrum treatment suitable for use in remote areas will be the key test in the next phase.